Kinezodianone R hydrochloride for Glaucoma, Suspect

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Dr EL-HARAZI, Glendale, CA
Glaucoma, Suspect+1 More
Kinezodianone R hydrochloride - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing the safety of a new drug, T4090. Kinezodianone R hydrochloride is a treatment for Glaucoma that is available free of charge. This treatment was previously approved by the FDA for a different condition.

Eligible Conditions

  • Glaucoma, Suspect
  • Glaucoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: up to 22 days

up to 22 days
Ocular and systemic adverse events

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

T4090
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

120 Total Participants · 2 Treatment Groups

Primary Treatment: Kinezodianone R hydrochloride · Has Placebo Group · Phase 1 & 2

T4090
Drug
Experimental Group · 1 Intervention: Kinezodianone R hydrochloride · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 22 days
Closest Location: Dr EL-HARAZI · Glendale, CA
Photo of california 1Photo of california 2Photo of california 3
N/AFirst Recorded Clinical Trial
0 TrialsResearching Glaucoma, Suspect
0 CompletedClinical Trials

Who is running the clinical trial?

Laboratoires TheaLead Sponsor
49 Previous Clinical Trials
5,832 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
Both eyes diagnosed open-angle glaucoma or ocular hypertension.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.